Laura Ferris
Specialist
3601 5th Ave, Suite 5a Falk Medical Building
Pittsburgh, PA 15213
- Medicare participating
At a glance
- Medical school
- University of Maryland School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 224
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Maryland School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
PA license MD426643
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 224
- Services billed
- 513
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 123 | 109 |
| Established patient office or other outpatient visit, 30-39 minutes | 93 | 77 |
| Destruction of precancer skin growth, 2-14 growths | 92 | 23 |
| Destruction of precancer skin growth, 1 growth | 53 | 45 |
| Biopsy of related skin growth, first growth | 48 | 43 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 31 | 31 |
| Destruction of skin growth, 1-14 growths | 22 | 19 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 19 | 15 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clobetasol Propionate Other prescribers in Pittsburgh, PA | 173 |
| Triamcinolone Acetonide Other prescribers in Pittsburgh, PA | 155 |
| Ketoconazole Other prescribers in Pittsburgh, PA | 132 |
| Methotrexate (methotrexate sodium) Other prescribers in Pittsburgh, PA | 115 |
| Tremfya (guselkumab) | 48 |
| Fluorouracil Other prescribers in Pittsburgh, PA | 43 |
| Skyrizi Pen (risankizumab-rzaa) | 43 |
| Skyrizi (risankizumab-rzaa) | 36 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Pittsburgh, PA | 36 |
| Taltz Autoinjector (ixekizumab) | 34 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 82 payments worth $84,499 in total to this clinician.
| Boehringer Ingelheim Pharma GmbH & Co.kg | $12,389 |
|---|---|
| Arcutis Biotherapeutics, Inc. | $9,943 |
| Boehringer Ingelheim International GmbH | $9,908 |
| Janssen Biotech, Inc. | $9,142 |
| Regeneron Pharmaceuticals, Inc. | $7,943 |
| E.r. Squibb & Sons, L.l.c. | $6,888 |
| Almirall LLC | $6,750 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $6,525 |
| Consulting Fee | $51,833 |
|---|---|
| Travel and Lodging | $17,529 |
| Compensation for services other than consulting (speaking, faculty) | $12,237 |
| Food and Beverage | $2,901 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharma GmbH & Co.kg Sep 19, 2025 | Travel and Lodging travel to Paris, France · in-kind | $9,628 |
| Janssen Biotech, Inc. Jul 12, 2025 | Consulting Fee TREMFYA · Immunology | $8,100 |
| Boehringer Ingelheim International GmbH Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,900 |
| Regeneron Pharmaceuticals, Inc. Apr 4, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $6,685 |
| Pfizer Inc. Aug 18, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $6,200 |
| E.r. Squibb & Sons, L.l.c. Sep 30, 2025 | Consulting Fee | $5,968 |
| Arcutis Biotherapeutics, Inc. Mar 13, 2025 | Consulting Fee Zoryve · Dermatology | $4,875 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 11, 2025 | Consulting Fee SPEVIGO · IMMUNOLOGY | $3,850 |
| Arcutis Biotherapeutics, Inc. Mar 13, 2025 | Travel and Lodging Zoryve · Dermatology · travel to Irving, TX | $3,750 |
| Sun Pharmaceutical Industries Inc. Feb 17, 2025 | Consulting Fee ILUMYA · Dermatology | $3,250 |
All 33 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Almirall LLC Nov 24, 2025 | Consulting Fee Klisyri; Seysara · Dermatology | $1,275 |
| Almirall LLC Nov 19, 2025 | Consulting Fee Seysara; Klisyri · Dermatology | $1,700 |
| UCB, Inc. Nov 13, 2025 | Consulting Fee Bimzelx · Immunology | $2,400 |
| Boehringer Ingelheim International GmbH Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,900 |
| Boehringer Ingelheim International GmbH Oct 22, 2025 | Consulting Fee | $2,850 |
| Boehringer Ingelheim International GmbH Oct 22, 2025 | Travel and Lodging travel to Paris, France · in-kind | $158 |
| E.r. Squibb & Sons, L.l.c. Sep 30, 2025 | Consulting Fee | $5,968 |
| Boehringer Ingelheim Pharma GmbH & Co.kg Sep 19, 2025 | Travel and Lodging travel to Paris, France · in-kind | $9,628 |
| Boehringer Ingelheim Pharma GmbH & Co.kg Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,037 |
| Boehringer Ingelheim Pharma GmbH & Co.kg Sep 19, 2025 | Travel and Lodging travel to Paris, France · in-kind | $674 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) SPEVIGO · IMMUNOLOGY | $2,500 |
| Pfizer Inc. Aug 18, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $6,200 |
| Janssen Biotech, Inc. Jul 12, 2025 | Consulting Fee TREMFYA · Immunology | $8,100 |
| Janssen Biotech, Inc. Jun 27, 2025 | Travel and Lodging TREMFYA · Immunology · travel to PHILADELPHIA, PA · in-kind | $525 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 27, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $337 |
| Janssen Biotech, Inc. Jun 27, 2025 | Travel and Lodging TREMFYA · Immunology · travel to PHILADELPHIA, PA · in-kind | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 27, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $316 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $300 |
| Arcutis Biotherapeutics, Inc. Jun 7, 2025 | Consulting Fee Zoryve · Dermatology | $750 |
| Regeneron Pharmaceuticals, Inc. Apr 4, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $6,685 |
| Regeneron Pharmaceuticals, Inc. Apr 4, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $955 |
| Almirall LLC Apr 2, 2025 | Consulting Fee Seysara; Klisyri · Dermatology | $2,975 |
| Arcutis Biotherapeutics, Inc. Mar 13, 2025 | Consulting Fee Zoryve · Dermatology | $4,875 |
| Arcutis Biotherapeutics, Inc. Mar 13, 2025 | Travel and Lodging Zoryve · Dermatology · travel to Irving, TX | $3,750 |
| Almirall LLC Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) | $800 |
| E.r. Squibb & Sons, L.l.c. Feb 26, 2025 | Travel and Lodging travel to JERSEY CITY, NJ | $143 |
| Arcutis Biotherapeutics, Inc. Feb 21, 2025 | Travel and Lodging Zoryve · Dermatology · travel to Irving, TX · in-kind | $568 |
| Sun Pharmaceutical Industries Inc. Feb 17, 2025 | Consulting Fee ILUMYA · Dermatology | $3,250 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 11, 2025 | Consulting Fee SPEVIGO · IMMUNOLOGY | $3,850 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 11, 2025 | Travel and Lodging SPEVIGO · IMMUNOLOGY · travel to Ridgefield, CT · in-kind | $140 |
| E.r. Squibb & Sons, L.l.c. Feb 7, 2025 | Travel and Lodging travel to Jersey City, NJ | $262 |
| E.r. Squibb & Sons, L.l.c. Feb 6, 2025 | Travel and Lodging travel to Jersey City, NJ | $279 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $147,066 in research payments for these studies, mostly to the institutions running them.
- TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
Janssen Research & Development, LLC - A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata
Arcutis Biotherapeutics, Inc. - A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASC…
Amgen Inc. - A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis
Incyte Corporation - A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Eli Lilly and Company · Completed · NCT03570749 - An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS)
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.